The United Kingdom and the United States have signed a landmark commercial pact that will keep zero duties on British drug products being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the public health system. This pledge secures that duties on these crucial goods will be held at zero for a timeframe of three years.
This agreement follows recent warnings to hike tariffs on patented drug products, with increases discussed reaching one hundred percent.
"This agreement with the Britain bolsters the global environment for new treatments and introduces much-needed fairness to American-British drug exports," a statement noted.
Commercial Impact
Medicines constitute one of the UK's largest exports to the US, which is clearly the primary buyer for leading British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of September, the UK shipped drugs worth over eleven billion pounds to the US. This value made up 17.4% of British export trade in that timeframe.
"This guarantee secures employment, boosts capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented.
Detailed British Pledges
The deal includes several notable commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase total health service expenditure on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be capped at 15%. Last year, refunds exceeded twenty percent.
Recent Tensions
The deal follows a long-running dispute between the sector and the UK government over spending levels and NHS adoption.
The disagreement were exacerbated by assertions that US consumers were charged a premium for the same drugs than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or cancelled, while substantial expansions have been pledged toward projects in the United States.
One official acknowledged that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
